We build a world-class pipeline by proprietary discovery platforms. Our innovation engine has been validated by clinical assets and global partnerships
H3 Antibody Technology
SynTracer® High Throughput
Endocytosis Platform
FlexiBody®
Bifunctional Platform
Biosion has developed a proprietary, state-of-the-art platform called H3 Antibody Technology that enables discovery of multiple therapeutic candidates with superior properties
High-Throughput
screening ranks the top candidates from thousands of target binders
High-Content
screening facilitates identification of lead candidates with superior and desired properties
High-Efficiency
guarantees productivity and success
Validated by clinical assets and global partnerships
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
We build a world-class pipeline by proprietary discovery platforms. Our innovation engine has been validated by clinical assets and global partnerships
H3 Antibody Technology
SynTracer® High Throughput
Endocytosis Platform
FlexiBody®
Bifunctional Platform
Biosion has developed a proprietary, state-of-the-art platform called H3 Antibody Technology that enables discovery of multiple therapeutic candidates with superior properties
High-Throughput
screening ranks the top candidates from thousands of target binders
High-Content
screening facilitates identification of lead candidates with superior and desired properties
High-Efficiency
guarantees productivity and success
Validated by clinical assets and global partnerships
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号